⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IMNN News
Imunon, Inc. Common Stock
IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer
globenewswire.com
IMNN
IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026
globenewswire.com
IMNN
Form 8-K
sec.gov
IMNN
IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY
globenewswire.com
IMNN
IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules
globenewswire.com
IMNN
IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026
globenewswire.com
IMNN
IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update
globenewswire.com
IMNN
IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer
globenewswire.com
IMNN
IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer
globenewswire.com
IMNN
IMUNON R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of IMNN-001 to Redefine Ovarian Cancer Treatment
globenewswire.com
IMNN